BioAtla, Inc.
- BCAB
- NASDAQ
- Biotechnology
- Conditionally Active Biologics
- Solid Tumor Oncology
$1.74
Today +31.44%Quote Aug 28, 2026, 08:00 PM UTC
−52.20%over the last month
Max drawdown −67.1%From 1-month high −53.7%3 months −57.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About BioAtla
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
41
Market value
$2.9M
Quote Aug 28
Analyst target
$250.00
+14309.2% from here
Floor
$1.08
37.8% below price
Resistance
$2.25
29.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BCABPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free